These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
193 related items for PubMed ID: 8840000
21. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. van 't Veer C, Mann KG. J Biol Chem; 1997 Feb 14; 272(7):4367-77. PubMed ID: 9020158 [Abstract] [Full Text] [Related]
22. Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition. Salemink I, Franssen J, Willems GM, Hemker HC, Lindhout T. J Biol Chem; 1999 Oct 01; 274(40):28225-32. PubMed ID: 10497177 [Abstract] [Full Text] [Related]
23. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans. Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Thromb Res; 1994 Sep 15; 75(6):609-16. PubMed ID: 7831680 [Abstract] [Full Text] [Related]
24. The role of the C-terminal domain in the inhibitory functions of tissue factor pathway inhibitor. Ettelaie C, Adam JM, James NJ, Oke AO, Harrison JA, Bunce TD, Bruckdorfer KR. FEBS Lett; 1999 Dec 17; 463(3):341-4. PubMed ID: 10606750 [Abstract] [Full Text] [Related]
28. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. Sevinsky JR, Rao LV, Ruf W. J Cell Biol; 1996 Apr 13; 133(2):293-304. PubMed ID: 8609163 [Abstract] [Full Text] [Related]
29. The effect of cell surface glycosaminoglycans (GAGs) on the inactivation of factor VIIa--tissue factor activity by antithrombin III. Hamamoto T, Kisiel W. Int J Hematol; 1998 Jul 13; 68(1):67-78. PubMed ID: 9713170 [Abstract] [Full Text] [Related]
30. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor. Iakhiaev A, Ruf W, Rao LV. Thromb Haemost; 2001 Mar 13; 85(3):458-63. PubMed ID: 11307815 [Abstract] [Full Text] [Related]
38. Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity. Dietzen DJ, Jack GG, Page KL, Tetzloff TA, Hall CL, Mast AE. Thromb Haemost; 2003 Jan 13; 89(1):65-73. PubMed ID: 12540955 [Abstract] [Full Text] [Related]
39. Tissue factor pathway inhibitor; its structure, function and clinical significance. Kato H. Pol J Pharmacol; 1996 Jan 13; 48(1):67-72. PubMed ID: 9112630 [Abstract] [Full Text] [Related]
40. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ. Blood Coagul Fibrinolysis; 1993 Oct 13; 4(5):661-9. PubMed ID: 8292716 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]